Guardant Health director plans $1.17M stock sale

A Guardant Health director filed a Rule 144 notice to potentially sell 6,674 GH shares previously received as equity compensation.

Available on EDGAR 09/16/2026 - 04:01 PM EDT Accepted by SEC EDGAR 09/16/2026 - 04:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) director Steve E. Krognes has filed a notice of proposed sale under Rule 144 for up to 6,674 shares of Guardant Health common stock held at Charles Schwab & Co., Inc. The shares were acquired on June 12, 2025 through a restricted stock lapse as equity compensation, with an aggregate market value listed as $1,172,886. The stock is listed on NASDAQ, and the filing notes 134,196,170 shares of common stock outstanding and an approximate sale date of September 16, 2026.

Key Figures

Shares proposed to be sold: 6,674 shares Aggregate market value of shares: $1,172,886 Shares outstanding: 134,196,170 shares +2 more

5 metrics

Shares proposed to be sold 6,674 shares Common stock to be sold under Rule 144 by director Steve E. Krognes

Aggregate market value of shares $1,172,886 Value for the 6,674 Guardant Health common shares covered by the notice

Shares outstanding 134,196,170 shares Guardant Health common stock outstanding as referenced in the Form 144

Approximate date of sale September 16, 2026 Date listed for proposed NASDAQ sale of the shares

Date of acquisition June 12, 2025 Date restricted stock lapsed and shares were acquired as equity compensation

Key Terms

Rule 144, Restricted Stock Lapse, Equity Compensation, Approximate Date of Sale

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Lapse financial

"Common | 06/12/2025 | Restricted Stock Lapse | Guardant Health, Inc."

Equity Compensation financial

"06/12/2025 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

Approximate Date of Sale financial

"134196170 | 09/16/2026 | NASDAQ"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Guardant Health (GH)?

It discloses that director Steve E. Krognes has filed a Rule 144 notice to potentially sell 6,674 shares of Guardant Health common stock, with an aggregate market value of $1,172,886, through Charles Schwab & Co., Inc. on NASDAQ.

How many Guardant Health (GH) shares is the director planning to sell?

The filing lists a proposed sale of 6,674 shares of Guardant Health common stock. This amount corresponds to shares acquired as equity compensation via a restricted stock lapse on June 12, 2025.

What is the reported market value of the Guardant Health (GH) shares in this Form 144?

The Form 144 states an aggregate market value of $1,172,886 for the 6,674 shares of Guardant Health common stock that are proposed to be sold under Rule 144.

When were the Guardant Health (GH) shares acquired and how?

The shares were acquired on June 12, 2025 through a Restricted Stock Lapse from Guardant Health, Inc., characterized in the filing as Equity Compensation.

What is the approximate sale timing for the Guardant Health (GH) shares in this notice?

The Form 144 lists an approximate date of sale of September 16, 2026 for the proposed sale of 6,674 Guardant Health common shares on NASDAQ.

How many Guardant Health (GH) shares are reported outstanding in this Form 144?

The filing reports 134,196,170 shares of Guardant Health common stock outstanding, providing context for the relative size of the 6,674-share proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001666236
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Guardant Health, Inc.
SEC File Number	001-38683
Address of Issuer	3100 HANOVER STREET PALO ALTO CALIFORNIA 94304
Phone	855-698-8887
Name of Person for Whose Account the Securities are To Be Sold	Krognes Steve E.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	6674	1172886.00	134196170	09/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/12/2025	Restricted Stock Lapse	Guardant Health, Inc.			6674	06/12/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Steve E. Krognes
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)